O
OrbiMed Portfolio holdings
AUM
$5.4B
Turnover
40.13%
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
-4.57%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$9.89B
AUM Growth
-$808M
(-7.6%)
Cap. Flow
+$275M
Cap. Flow
% of AUM
2.78%
Top 10 Holdings %
Top 10 Hldgs %
30.49%
Holding
183
New
24
Increased
25
Reduced
25
Closed
24
Avg Time Held Equity + Options
1.7
years
Top 10 Avg Time Held Equity + Options
0.5
years
Top 20 Avg Time Held Equity + Options
1.6
years
Avg Time Held Equity only
1.7
years
Top 10 Avg Time Held Equity only
0.5
years
Top 20 Avg Time Held Equity only
1.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Biotech ETF
XBI
|
+$123M |
| 2 |
Neuropace
NPCE
|
+$93.1M |
| 3 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$77.8M |
| 4 |
Janux Therapeutics
JANX
|
+$77.2M |
| 5 |
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$74.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Haemonetics
HAE
|
+$94.6M |
| 2 |
AbCellera Biologics
ABCL
|
+$54.5M |
| 3 |
Adverum Biotechnologies
ADVM
|
+$54.2M |
| 4 |
Molina Healthcare
MOH
|
+$38M |
| 5 |
PAND
Pandion Therapeutics Inc. Common Stock
PAND
|
+$31.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.72% |
| 2 | Miscellaneous | 4.15% |
| 3 | Technology | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Thermo Fisher Scientific
TMO
$249B
| $55.6M | 0.56% |
110,300
| – | – |
2013 Q2
32 quarters
|
|
52
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $54.9M | 0.56% |
+66,617
| New | +$51.6M |
2021 Q2
0 quarters
|
|
53
Mereo BioPharma
MREO
$49.4M
| – | – |
0
| – | – |
2020 Q4
2 quarters
|
|
54
Burning Rock Biotech
BNR
$154M
| $54.7M | 0.55% |
185,620
-4,146
| -2% | -$1.23M |
2020 Q2
4 quarters
|
|
55
DELISTED
Select Medical
SEM
| $53.7M | 0.54% |
+2,359,162
| New | +$49M |
2021 Q2
0 quarters
|
|
56
Chemomab Therapeutics
CMMB
$9.45M
| $49M | 0.5% |
644,544
| – | – |
2021 Q1
1 quarter
|
|
57
TELA Bio
TELA
$49.2M
| $48.8M | 0.49% |
3,027,542
| – | – |
2019 Q4
6 quarters
|
|
58
DELISTED
Applied Therapeutics
APLT
| $46.9M | 0.47% |
2,257,387
| – | – |
2019 Q4
6 quarters
|
|
59
DELISTED
Terns Pharmaceuticals
TERN
| $46.5M | 0.47% |
3,791,204
| – | – |
2021 Q1
1 quarter
|
|
60
VistaGen Therapeutics
VTGN
$9.17M
| $45.6M | 0.46% |
482,262
+195,462
| +68% | +$14.5M |
2020 Q4
2 quarters
|
|
|
DBTX
61
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
| $42.5M | 0.43% |
4,945,192
| – | – |
2021 Q1
1 quarter
|
|
62
Novavax
NVAX
$2.08B
| $42.5M | 0.43% |
200,295
+44,462
| +29% | +$8.15M |
2021 Q1
1 quarter
|
|
|
TCDA
63
DELISTED
Tricida, Inc. Common Stock
TCDA
| $41.5M | 0.42% |
9,614,280
| – | – |
2018 Q2
12 quarters
|
|
64
Oric Pharmaceuticals
ORIC
$1.2B
| $41.4M | 0.42% |
2,337,574
| – | – |
2020 Q2
4 quarters
|
|
65
ImageneBio Inc
IMA
$47.1M
| $41.2M | 0.42% |
244,495
| – | – |
2021 Q1
1 quarter
|
|
66
SI-BONE Inc
SIBN
$873M
| $41.1M | 0.42% |
1,305,300
| – | – |
2020 Q1
5 quarters
|
|
67
DELISTED
Mersana Therapeutics
MRSN
| $38M | 0.38% |
112,010
+36,310
| +48% | +$13.7M |
2019 Q1
9 quarters
|
|
68
Disc Medicine
IRON
$2.14B
| $37.7M | 0.38% |
194,207
| – | – |
2021 Q1
1 quarter
|
|
|
LOGC
69
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
| $37.6M | 0.38% |
8,466,783
| – | – |
2018 Q4
10 quarters
|
|
|
VRNA
70
DELISTED
Verona Pharma
VRNA
| $37.2M | 0.38% |
5,694,841
| – | – |
2017 Q2
16 quarters
|
|
|
HARP
71
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $36.2M | 0.37% |
261,131
+32,561
| +14% | +$6.21M |
2019 Q1
9 quarters
|
|
|
NSTG
72
DELISTED
NanoString Technologies, Inc.
NSTG
| $36M | 0.36% |
556,000
-66,900
| -11% | -$4.25M |
2020 Q1
5 quarters
|
|
73
LENZ Therapeutics
LENZ
$108M
| $34M | 0.34% |
+158,044
| New | +$27.5M |
2021 Q2
0 quarters
|
|
|
TRIL
74
DELISTED
Trillium Therapeutics Inc.
TRIL
| $32.2M | 0.33% |
3,322,300
+157,100
| +5% | +$1.48M |
2020 Q1
5 quarters
|
|
75
GH Research
GHRS
$1.27B
| $31M | 0.31% |
+1,428,666
| New | +$29.2M |
2021 Q2
0 quarters
|
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q2 2021 Portfolio in Review
As of Q2 2021, OrbiMed held 183 positions worth $9.89B, down 7.6% from $10.7B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
OrbiMed's Q2 2021 filing shows 24 new, 25 increased, 25 reduced and 24 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M. The largest sale was Haemonetics, an estimated $94.6M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Technology.
- OrbiMed's largest Q2 2021 buy was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M.
- OrbiMed added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2021, an estimated $74.2M increase.
- OrbiMed's biggest Q2 2021 reduction was AbCellera Biologics, cutting an estimated $54.5M.
- OrbiMed fully exited Haemonetics in Q2 2021, selling an estimated $94.6M.
- OrbiMed's ten largest holdings make up 30% of its $9.89B portfolio in Q2 2021.
- OrbiMed opened 24 new positions and closed 24 in Q2 2021.
- OrbiMed's portfolio value fell 7.6% quarter-over-quarter to $9.89B.
Based on OrbiMed's 13F filing for Q2 2021, filed 16 Aug 2021.